Multimedia Delivery Can Enhance the Consent Process
New technologies allow prospective subjects to absorb information about a trial at each individual?s pace.
Recent deaths of human subjects at leading medical research facilities and the consequent major lawsuits leveled against those facilities have brought the current consent process under attack. Human subject advocacy groups, federal institutions, trial attorneys, and medical ethiciststo name a few of the interested groupshave all called for an improved consent process.13 Such a process must fully educate subjects about a clinical trial protocol and the trials purpose, risks, and expected results. The financial backers of the trial and the possible financial beneficiaries must be made known, and potential conflicts of interest must be disclosed. The informed consent of the future will verify that the subject truly understands these concepts, and that all concerns have been resolved prior to consent being given. This is the ideal of informed consent that the clinical trials industry seeks and, for its own protection, must soon adopt.
New technologies, such as multimedia presentations, aim to rectify the deficiencies of the current consent process. These presentations educate the subject through a variety of teaching techniquesnarration, illustrations, photos, text, and animationsthat now seem commonplace in our television-based society. More than a quixotic hope for the future, enhanced informed consent technology has already been implemented in several leading research centers. These multimedia technologies claim to deliver benefits to both the investigative team and the subject, and may soon prove to be a revolutionizing force in the consent process.
Problems in the current consent process
Several factors are hampering current efforts to provide research subjects with a comprehensive consent experience. A few of these factors include:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
